What KRKA Pharma does

KRKA Pharma is a joint venture established in 2024 between Slovenia-based Krka Group, a €1.9 billion+ generic and branded-generic pharmaceutical manufacturer with 70+ years of operating history and 18 billion+ tablets/capsules produced annually, and India-based Laurus Labs, a vertically integrated pharmaceutical company with ₹6,041 crore in revenue, 6,972 employees, and 2,586 R&D personnel. The company is headquartered in Hyderabad, India, and is purpose-built to develop and manufacture generic pharmaceutical products for the Indian market and global export, leveraging Krka's formulation, regulatory, and distribution expertise alongside Laurus's API synthesis and large-scale manufacturing capability.

The company's core product strategy centers on generic pharmaceuticals — small-molecule oral solids and related dosage forms — developed and produced at greenfield facilities currently under construction in Genome Valley, Hyderabad. Technology and platform components are inherited rather than invented: Krka contributes its formulation know-how, regulatory dossiers, and USFDA/EMA/WHO compliance track record, while Laurus contributes API process IP and manufacturing scale. The technology stack is conventional pharmaceutical manufacturing rather than a novel platform.

The business model is standard generic-pharma economics: develop and manufacture off-patent molecules, sell into regulated and semi-regulated markets via distribution channels inherited from Krka (which operates in 70+ markets) and Laurus. The company holds ISO 27001 certification as an early compliance signal. Revenue mechanics — pricing model, contract structures, customer segments — are not yet disclosed because the company is pre-commercial, with no products launched and no named customers at the JV level. The single named director is Boštjan Perše.

Name

KRKA Pharma

Legal name

KRKA Pharma Private Limited

Website

https://krkapharmaindia.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

KRKA Pharma is a 2024 Hyderabad-based joint venture between Krka Group (Slovenia) and Laurus Labs (India) developing and manufacturing generic pharmaceuticals for India and global export markets via greenfield facilities in Genome Valley.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Drug formulation development
• Pharmaceutical joint venture

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Core offering

KRKA Pharma develops and manufactures generic pharmaceutical products for India and global markets. The company is a 2024 joint venture between Krka Group (Slovenia) and Laurus Labs (India), currently constructing manufacturing and R&D facilities in Genome Valley, Hyderabad. Its core offering focuses on quality generic medicines, with capabilities inherited from parent companies spanning formulation development, API manufacturing, CDMO services, and large-scale production of tablets and capsules.

Product overview

KRKA Pharma Pvt. Ltd. is a joint venture pharmaceutical company established in 2024 by Krka, d. d., Novo mesto, Slovenia and Laurus Labs Ltd., India. The company is constructing manufacturing and R&D facilities in Genome Valley, Hyderabad, with a vision to develop and manufacture pharmaceutical products for India and global markets. The company focuses on generic pharmaceutical products, inheriting quality standards and product development capabilities from its parent companies, Krka Group and Laurus Labs.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic pharmaceutical products KRKA Pharma's core offering comprises generic pharmaceutical finished dosage forms developed and manufactured for healthcare providers and pharmaceutical markets in India and globally. The product portfolio inherits formulation development and quality standards from parent company Krka Group, which produces 18 billion+ tablets and capsules annually.

Quantifiable outcome

• 18 billion+ tablets and capsules produced annually by parent company Krka Group

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Krka, d. d., Novo mesto, SloveniacoreStrategic or Co-development Partner · 1 January 2024Krka Group is a Europe-based generic pharmaceutical corporation with 70 years of experience, generating €1.9 billion+ annually in product and service sales. They contribute top-end quality products, innovative solutions, and extensive production, registration, and marketing-and-sales network to the joint venture.
• Laurus Labs Ltd., IndiacoreStrategic or Co-development Partner · 1 January 2024Laurus Labs is a research-driven pharmaceutical and biotechnology company founded in 2005, generating ₹6,041 crore in FY2023 revenue. They bring CDMO services, global regulatory expertise (USFDA, WHO, EMA, etc.), and API leadership in anti-retroviral, oncology, cardiovascular, and gastro therapeutics to the joint venture.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lupin Limited: India-headquartered generic pharmaceutical company with global manufacturing footprint across formulations and APIs. Directly comparable as a generic finished-dose manufacturer serving India, US, and other regulated markets.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company and a dominant generic drug manufacturer with extensive domestic and global operations. Directly comparable as a finished-dose generic manufacturer targeting both Indian and international markets, though far larger and more diversified.
• Sandoz (Novartis): Global generic and biosimilar pharmaceutical company spun out of Novartis with strong European heritage similar to Krka's positioning. Comparable as a high-quality European-headquartered generics manufacturer with global ambitions and emerging market reach.
• Cipla: One of India's leading generic pharmaceutical manufacturers with a strong presence in respiratory, anti-retroviral, and chronic therapies. Comparable as a finished-dose generic manufacturer serving India and emerging markets, with overlap in Laurus Labs' therapeutic focus areas.
• Aurobindo Pharma: Vertically integrated Indian generic manufacturer with strong API-to-formulation integration, similar in strategic positioning to what KRKA Pharma aims to build through its Laurus Labs parentage. Compares closely as a generics manufacturer with significant US and European market exposure.
• Dr. Reddy's Laboratories: Major India-based generic pharmaceutical company with strong API and finished-dose capabilities across global regulated markets. Directly comparable business model (generic formulations for India + global), though with a far larger commercial footprint and product portfolio.
• Zydus Lifesciences (Cadila Healthcare): Indian pharmaceutical company with end-to-end capabilities from APIs to finished formulations, including biosimilars. Comparable as a domestic Indian generic manufacturer with global market presence and integrated value chain.

Direct peers

• Laurus Labs: Parent company of KRKA Pharma and itself an Indian API + CDMO player with global leadership in select APIs (anti-retroviral, oncology, cardiovascular, gastro). Closely comparable given KRKA Pharma inherits Laurus Labs' CDMO, regulatory, and API expertise for finished-dose development.
• Krka, d. d., Novo mesto: Parent company of KRKA Pharma and one of Europe's largest generic pharmaceutical companies with €1.9B+ revenue and 18B+ tablets/capsules produced annually. Directly comparable business model (small-molecule generics for global markets) and shares product-development and manufacturing DNA with KRKA Pharma.

Others

• Teva Pharmaceutical Industries:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KRKA Pharma